+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID05867251

First-in-Human Study of AVZO-021 to Assess Safety, Pharmacokinetics, and Antitumor Activity Alone and With Other Therapies in Advanced Solid Tumors

Led by Avenzo Therapeutics, Inc. · Updated on 2026-09-28

430

Participants Needed

13

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying AVZO-021, an oral medication that inhibits cyclin-dependent kinase 2 CDK2, in patients with advanced solid tumors. This Phase 12, first-in-human, open-label, nonrandomized trial aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021. The study focuses on tumors including HRHER2- breast cancer and CCNE1 altered malignancies, where standard treatments may no longer be effective or safe. Participants receive escalating doses of AVZO-021 once daily in 28-day cycles as monotherapy or in combination with other cancer therapies such as fulvestrant, palbociclib, ribociclib, abemaciclib, sacituzumab govitecan-hziy, or carboplatin. The study includes a dose-escalation phase to determine the recommended phase 2 dose and a dose-expansion phase to assess antitumor activity. Different cohorts receive AVZO-021 alone or combined with these agents depending on their cancer type and treatment history. During the study, participants undergo regular evaluations including monitoring for dose-limiting toxicities and treatment-emergent adverse events. Pharmacokinetic assessments are performed during the first cycle to measure drug concentration and metabolism. Researchers measure tumor response, progression-free survival, overall survival, and duration of response. Safety and laboratory tests are conducted throughout the study. Participation may last several months or longer depending on treatment response and tolerability.

CONDITIONS

Brief Title

Study of AVZO-021 in Patients With Advanced Solid Tumors

Research Team

M

Medical Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here